(Q53217028)

12 May 2018

title

Current role of echinocandins in the management of invasive aspergillosis. (English)

1 reference

12 May 2018

2

Claudio Viscoli

1 reference

12 May 2018

author name string

Małgorzata Mikulska

series ordinal

1

1 reference

12 May 2018

publication date

1 December 2011

1 reference

12 May 2018

Current infectious disease reports

published in

1 reference

12 May 2018

volume

13

1 reference

12 May 2018

issue

6

1 reference

12 May 2018

page(s)

517-527

1 reference

12 May 2018

In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

A case of Aspergillus empyema successfully treated with combination therapy of voriconazole and micafungin: excellent penetration of voriconazole and micafungin into pleural fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

X-linked severe combined immunodeficiency (X-SCID) with high blood levels of immunoglobulins and Aspergillus pneumonia successfully treated with micafangin followed by unrelated cord blood stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Echinocandin antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Role of (1-->3)-beta-D-glucan in the diagnosis of invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Echinocandin antifungal drugs in fungal infections: a comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Anidulafungin versus fluconazole for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Use of Antifungal Combination Therapy: Agents, Order, and Timing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

In vitro activity and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Micafungin: a new echinocandin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Combination therapy for invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

In vitro interactions of itraconazole and micafungin against clinically important filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Invasive aspergillosis: diagnosis, prophylaxis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Antifungal prophylaxis with micafungin in neutropenic patients with hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Antifungal prophylaxis with micafungin in patients treated for childhood cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

When primary antifungal therapy fails

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in haematological cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Combination antifungal therapy for invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-011-0216-6

β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis

21 January 2018

1 reference

12 December 2020

Evaluation of the safety and efficacy of micafungin in Japanese patients with deep mycosis: a post-marketing survey report

1 reference

12 December 2020

Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

1 reference

12 December 2020

Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis

1 reference

12 December 2020

Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY

1 reference

12 December 2020

10.1007/S11908-011-0216-6

Identifiers

DOI

1 reference

12 May 2018

release_o5zl76soazggtey4xmpwbfyoya

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/o5zl76soazggtey4xmpwbfyoya

24 November 2022

mapped directly with Wikidata item

1 reference

12 May 2018